The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | SKIPPirr: reducing amivantamab-related IRRs in EGFR-m NSCLC
Gilberto Lopes, MD, University of Miami, Miami, FL, discusses the Phase II SKIPPirr study (NCT05663866), which evaluated strategies to reduce infusion-related reactions (IRRs) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) treated with amivantamab and lazertinib. Dexamethasone resulted in meaningful reduction in IRR incidence compared to historical data. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
